| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 413 |
| 1 | IBRUTINIB | 358 |
| 2 | LENALIDOMIDE | 256 |
| 3 | BORTEZOMIB | 211 |
| 4 | VENETOCLAX | 177 |
| 5 | CYCLOPHOSPHAMIDE | 156 |
| 6 | CYCLOPHOSPHAMIDE FOR INJECTION | 156 |
| 7 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 156 |
| 8 | PREDNISONE | 145 |
| 9 | CYTARABINE | 131 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ALUMINUM CHLOROHYDRATE | 1 | 0.0263 |
| 1 | GLOFITAMAB | 30 | 0.0163 |
| 2 | BREXUCABTAGENE AUTOLEUCEL | 28 | 0.0152 |
| 3 | RITUXIMAB-ABBS | 40 | 0.0084 |
| 4 | BENDAMUSTINE HCL | 93 | 0.0063 |
| 5 | CARMUSTINE | 28 | 0.0063 |
| 6 | IBRITUMOMAB TIUXETAN | 9 | 0.0059 |
| 7 | PIRTOBRUTINIB | 3 | 0.0051 |
| 8 | ZANUBRUTINIB | 18 | 0.0051 |
| 9 | IBRUTINIB | 358 | 0.0045 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 469 |
| 1 | Kinase Inhibitor [EPC] | 411 |
| 2 | Corticosteroid [EPC] | 260 |
| 3 | Thalidomide Analog [EPC] | 258 |
| 4 | Proteasome Inhibitor [EPC] | 212 |
| 5 | BCL-2 Inhibitor [EPC] | 177 |
| 6 | Alkylating Drug [EPC] | 168 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 137 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 82 |
| 9 | Xanthine Oxidase Inhibitor [EPC] | 70 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 30 | 0.0103 |
| 1 | BCL-2 Inhibitor [EPC] | 177 | 0.0031 |
| 2 | Proteasome Inhibitor [EPC] | 212 | 0.0019 |
| 3 | Non-Standardized Pollen Allergenic Extract [EPC] | 1 | 0.0018 |
| 4 | Standardized Pollen Allergenic Extract [EPC] | 1 | 0.0018 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 469 | 0.0015 |
| 6 | Interferon gamma [EPC] | 2 | 0.0014 |
| 7 | Pyruvate Kinase Activator [EPC] | 1 | 0.0014 |
| 8 | Kinase Inhibitor [EPC] | 411 | 0.0008 |
| 9 | Alkylating Drug [EPC] | 168 | 0.0007 |